Andrew C Gordon1,2, Sarah B White3, Vanessa L Gates1, Weiguo Li1, Daniel Procissi1, Zhuoli Zhang1, Kathleen R Harris1, Dong-Hyun Kim1, Samdeep K Mouli1, Reed A Omary4, Riad Salem1,5,6, Andrew C Larson1,2,4, Robert J Lewandowski7,8,9. 1. Department of Radiology, Northwestern University Feinberg School of Medicine, 676 N. St. Clair, Suite 800, Chicago, IL, 60611, USA. 2. Department of Biomedical Engineering, Northwestern University, Evanston, IL, USA. 3. Division of Vascular and Interventional Radiology, Department of Radiology, Medical College of Wisconsin, Milwaukee, WI, USA. 4. Department of Radiology and Radiological Sciences, Vanderbilt University, Nashville, TN, USA. 5. Department of Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 6. Department of Surgery-Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 7. Department of Radiology, Northwestern University Feinberg School of Medicine, 676 N. St. Clair, Suite 800, Chicago, IL, 60611, USA. r-lewandowski@northwestern.edu. 8. Department of Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. r-lewandowski@northwestern.edu. 9. Department of Surgery-Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. r-lewandowski@northwestern.edu.
Abstract
PURPOSE: Portal vein embolization (PVE) is an established neoadjuvant method to induce future liver remnant hypertrophy prior to surgical resection of hepatic tumors. The purpose of our study was to examine the feasibility of PVE with glass 90Y microspheres (Y90 PVE) in Sprague-Dawley rats. We tested the hypothesis that increased doses of Y90 PVE would increase target lobe fibrosis and atrophy. METHODS: Twenty-two rats were assigned to four groups for Y90 PVE to the right median lobe: very high- (273.8 MBq; n = 2), high- (99.9 MBq; n = 10), medium- (48.1 MBq; n = 5), and low-dose (14.8 MBq; n = 5). An untreated control group included seven rats. 90Y PET/CT of 90Y distributions confirmed lobar targeting. MRI volumes were measured at baseline, 2-, 4-, 8- and 12-weeks. Explanted hepatic lobes were weighed, sectioned, and stained for H&E and immunohistochemistry. Digitized slides allowed quantitative measurements of fibrosis (20 foci/slide). RESULTS: Ex vivo measurements confirmed 91-97% activity was localized to the target lobe (n = 4). The percent growth of the target lobe relative to baseline was - 5.0% (95% CI - 17.0-6.9%) for high-, medium dose rats compared to + 18.6% (95% CI + 7.6-29.7%) in the low-dose group at 12-weeks (p = 0.0043). Radiation fibrosis increased in a dose-dependent fashion. Fibrotic area/microsphere was 22,893.5, 14,946.2 ± 2253.3, 15,304.5 ± 4716.6, and 5268.8 ± 2297.2 μm2 for very high- (n = 1), high- (n = 4), medium- (n = 3), and low-dose groups (n = 5), respectively. CONCLUSION: Y90 PVE was feasible in the rat model, resulted in target lobe atrophy, and dose-dependent increases in hepatic fibrosis at 12 weeks. The onset of imaging-based volumetric changes was 8-12 weeks.
PURPOSE: Portal vein embolization (PVE) is an established neoadjuvant method to induce future liver remnant hypertrophy prior to surgical resection of hepatic tumors. The purpose of our study was to examine the feasibility of PVE with glass 90Y microspheres (Y90 PVE) in Sprague-Dawley rats. We tested the hypothesis that increased doses of Y90 PVE would increase target lobe fibrosis and atrophy. METHODS: Twenty-two rats were assigned to four groups for Y90 PVE to the right median lobe: very high- (273.8 MBq; n = 2), high- (99.9 MBq; n = 10), medium- (48.1 MBq; n = 5), and low-dose (14.8 MBq; n = 5). An untreated control group included seven rats. 90Y PET/CT of 90Y distributions confirmed lobar targeting. MRI volumes were measured at baseline, 2-, 4-, 8- and 12-weeks. Explanted hepatic lobes were weighed, sectioned, and stained for H&E and immunohistochemistry. Digitized slides allowed quantitative measurements of fibrosis (20 foci/slide). RESULTS: Ex vivo measurements confirmed 91-97% activity was localized to the target lobe (n = 4). The percent growth of the target lobe relative to baseline was - 5.0% (95% CI - 17.0-6.9%) for high-, medium dose rats compared to + 18.6% (95% CI + 7.6-29.7%) in the low-dose group at 12-weeks (p = 0.0043). Radiation fibrosis increased in a dose-dependent fashion. Fibrotic area/microsphere was 22,893.5, 14,946.2 ± 2253.3, 15,304.5 ± 4716.6, and 5268.8 ± 2297.2 μm2 for very high- (n = 1), high- (n = 4), medium- (n = 3), and low-dose groups (n = 5), respectively. CONCLUSION: Y90 PVE was feasible in the rat model, resulted in target lobe atrophy, and dose-dependent increases in hepatic fibrosis at 12 weeks. The onset of imaging-based volumetric changes was 8-12 weeks.
Authors: Wilmar de Graaf; Jacomina W van den Esschert; Krijn P van Lienden; Joris J T H Roelofs; Thomas M van Gulik Journal: J Surg Res Date: 2010-05-21 Impact factor: 2.192
Authors: T F Jakobs; S Saleem; B Atassi; E Reda; R J Lewandowski; V Yaghmai; F Miller; R K Ryu; S Ibrahim; K T Sato; L M Kulik; M F Mulcahy; R Omary; R Murthy; M F Reiser; R Salem Journal: Dig Dis Sci Date: 2008-01-31 Impact factor: 3.199
Authors: Ryan Hickey; Mary F Mulcahy; Robert J Lewandowski; Vanessa L Gates; Michael Vouche; Ali Habib; Sheetal Kircher; Steven Newman; Halla Nimeiri; Al B Benson; Riad Salem Journal: Int J Radiat Oncol Biol Phys Date: 2014-04-01 Impact factor: 7.038
Authors: Constanze Sänger; Andrea Schenk; Lars Ole Schwen; Lei Wang; Felix Gremse; Sara Zafarnia; Fabian Kiessling; Chichi Xie; Weiwei Wei; Beate Richter; Olaf Dirsch; Uta Dahmen Journal: PLoS One Date: 2015-11-30 Impact factor: 3.240
Authors: María Páramo; Eva Santamaría; Miguel A Idoate; Macarena Rodríguez-Fraile; Alberto Benito; Maria Collantes; Gemma Quincoces; Iván Peñuelas; Carmen Berasain; Josepmaria Argemi; Jorge Quiroga; Bruno Sangro; José I Bilbao; Mercedes Iñarrairaegui Journal: Sci Rep Date: 2022-02-02 Impact factor: 4.379